Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gunhild Hagen is active.

Publication


Featured researches published by Gunhild Hagen.


The Lancet | 2015

Comprehensive geriatric care for patients with hip fractures: a prospective, randomised, controlled trial

Anders Prestmo; Gunhild Hagen; Olav Sletvold; Jorunn L. Helbostad; Pernille Thingstad; Kristin Taraldsen; Stian Lydersen; Vidar Halsteinli; Turi Saltnes; Sarah E Lamb; Lars Gunnar Johnsen; Ingvild Saltvedt

BACKGROUND Most patients with hip fractures are characterised by older age (>70 years), frailty, and functional deterioration, and their long-term outcomes are poor with increased costs. We compared the effectiveness and cost-effectiveness of giving these patients comprehensive geriatric care in a dedicated geriatric ward versus the usual orthopaedic care. METHODS We did a prospective, single-centre, randomised, parallel-group, controlled trial. Between April 18, 2008, and Dec 30, 2010, we randomly assigned home-dwelling patients with hip-fractures aged 70 years or older who were able to walk 10 m before their fracture, to either comprehensive geriatric care or orthopaedic care in the emergency department, to achieve the required sample of 400 patients. Randomisation was achieved via a web-based, computer-generated, block method with unknown block sizes. The primary outcome, analysed by intention to treat, was mobility measured with the Short Physical Performance Battery (SPPB) 4 months after surgery for the fracture. The type of treatment was not concealed from the patients or staff delivering the care, and assessors were only partly masked to the treatment during follow-up. This trial is registered with ClinicalTrials.gov, number NCT00667914. FINDINGS We assessed 1077 patients for eligibility, and excluded 680, mainly for not meeting the inclusion criteria such as living in a nursing home or being aged less than 70 years. Of the remaining patients, we randomly assigned 198 to comprehensive geriatric care and 199 to orthopaedic care. At 4 months, 174 patients remained in the comprehensive geriatric care group and 170 in the orthopaedic care group; the main reason for dropout was death. Mean SPPB scores at 4 months were 5·12 (SE 0·20) for comprehensive geriatric care and 4·38 (SE 0·20) for orthopaedic care (between-group difference 0·74, 95% CI 0·18-1·30, p=0·010). INTERPRETATION Immediate admission of patients aged 70 years or more with a hip fracture to comprehensive geriatric care in a dedicated ward improved mobility at 4 months, compared with the usual orthopaedic care. The results suggest that the treatment of older patients with hip fractures should be organised as orthogeriatric care. FUNDING Norwegian Research Council, Central Norway Regional Health Authority, St Olav Hospital Trust and Fund for Research and Innovation, Liaison Committee between Central Norway Regional Health Authority and the Norwegian University of Science and Technology, the Department of Neuroscience at the Norwegian University of Science and Technology, Foundation for Scientific and Industrial Research at the Norwegian Institute of Technology (SINTEF), and the Municipality of Trondheim.


International Journal of Technology Assessment in Health Care | 2013

New anticoagulants as thromboprophylaxis after total hip or knee replacement.

Vida Hamidi; Tove Ringerike; Gunhild Hagen; Åsmund Reikvam; Marianne Klemp

OBJECTIVES Due to a high risk of thromboembolism in patients undergoing major orthopedic surgery, it has become standard practice to give thromboprophylactic treatment. We assessed the relative efficacy and cost-effectiveness of two new oral anticoagulants, rivaroxaban and dabigatran, relative to subcutaneous enoxaparin for the prevention of thromboembolism after total hip replacement (THR) and total knee replacement surgery (TKR). METHODS We conducted a systematic review of the literature to assess efficacy and safety, and evaluated quality of documentation using GRADE. Cost-effectiveness was assessed by developing a decision model. The model combined two modules; a decision tree for the short-term prophylaxis and a Markov model for the long-term complications and survival gain. RESULTS For rivaroxaban compared with enoxaparin, we found statistically significant decreases in deep vein thrombosis, but also a trend toward increased risk of major bleeding. For mortality and pulmonary embolism there were no statistically significant differences between the treatments. We did not find statistically significant differences between dabigatran and enoxaparin for our efficacy and safety outcomes. Assuming a willingness to pay of EUR62,500 per QALY, rivaroxaban following THR had a probability of 38 percent, and enoxaparin following TKR had a probability of 34 percent of being cost-effective. Clinical efficacy had the greatest impact on decision uncertainty. CONCLUSIONS Dabigatran and rivaroxaban are comparable with enoxaparin following THR and TKR regarding the efficacy and safety outcomes. However, there is great uncertainty regarding which strategy is the most cost-effective. More research on clinical efficacy of rivaroxaban and dabigatran is likely to change our results.


Physiotherapy Research International | 2015

Effectiveness of task specific gait and balance exercise 4 months after hip fracture: protocol of a randomized controlled trial--the Eva-hip study.

Pernille Thingstad; Kristin Taraldsen; Gunhild Hagen; Sylvi Sand; Ingvild Saltvedt; Olav Sletvold; Jorunn L. Helbostad

BACKGROUND AND PURPOSE Regular rehabilitation is not sufficient for regaining function after a hip fracture, and more targeted interventions for home-dwelling elderly hip-fracture patients are needed. This paper describes the protocol of a study assessing the effectiveness and cost effectiveness of a task specific progressive gait and balance exercise programme for hip-fracture patients, performed 4 months after the fracture. METHODS/DESIGN A single blind two-arm pragmatic randomised controlled trial was conducted with 142 hip-fracture patients randomized to a 10-week home-based exercise programme or to practice as usual 4 months following the surgery. Inclusion criteria were age >70 years and being home dwelling prior to the fracture. Exclusion criteria are life expectancy <3 months and inability to walk 10 m prior to the fracture. The content and organization of the programme was developed in collaboration between physiotherapy researchers and primary health-care physiotherapists. Participants were followed for 1 year post-surgery, evaluating short-term and long-term effects of the programme. The primary outcome is gait speed, and the secondary outcomes are spatial and temporal gait parameters, free living physical behaviour by activity monitoring, mobility performance, activities of daily living, fear of falling, cognitive function, depression and health-related quality of life. Cost-effectiveness analysis is planned. DISCUSSION This paper describes a task specific exercise programme aimed to improve gait and balance after a hip fracture. Inclusion started in February 2011, and the last 1-year follow-up is performed in March 2014. Broad inclusion criteria and physiotherapy-guided home-based exercises may facilitate the participation from frail patients and thereby increase the generalizability of the findings. Development and completion of the intervention within routine clinical practice will enlighten the implementation of results into clinical practice. Results may add new insight into how physiotherapy can improve gait and thereby activity and functioning in everyday life and have implications on future content and organization of physiotherapy after a hip fracture.


PharmacoEconomics | 2014

Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010

Torbjørn Wisløff; Gunhild Hagen; Vida Hamidi; Espen Movik; Marianne Klemp; Jan Abel Olsen


PharmacoEconomics | 2014

Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.

Torbjørn Wisløff; Gunhild Hagen; Marianne Klemp


79 | 2013

Efficacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fibrillation

Torbjørn Wisløff; Tove Ringerike; Gunhild Hagen; Åsmund Reikvam; Marianne Klemp


194 | 2012

Tidlig ultralyd i svangerskapsomsorgen

Vigdis Lauvrak; Inger Natvig Norderhaug; Gunhild Hagen; Espen Movik; Ganesh Acharya; Anne Forus; Bjørn Hofmann; Synnøve Lian Johnsen; Anne Kaasen; Kari Klungsøyr Melve; Trond Markestad; Kjell Å Salvesen; Annetine Staff; Gisle Roksund; Marianne Klemp; Brynjar Fure


Archive | 2011

Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery

Tove Ringerike; Vida Hamidi; Gunhild Hagen; Åsmund Reikvam; Marianne Klemp


Archive | 2011

Efficacy and cost-effectiveness of alendronate for the prevention of fractures in postmenopausal women in Norway

Gunhild Hagen; Torbjørn Wisløff; Jan A. Falch; C. M. Lofthus; Frede Frihagen; Knut-Arne Wensaas; Lars Granum; Janicke Nevjar; Ivar Sønbø Kristiansen; Marianne Klemp


Osteoporosis International | 2016

The predicted lifetime costs and health consequences of calcium and vitamin D supplementation for fracture prevention—the impact of cardiovascular effects

Gunhild Hagen; Torbjørn Wisløff; Ivar Sønbø Kristiansen

Collaboration


Dive into the Gunhild Hagen's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Torbjørn Wisløff

Norwegian Institute of Public Health

View shared research outputs
Top Co-Authors

Avatar

Kristin Taraldsen

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Olav Sletvold

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Pernille Thingstad

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Tove Ringerike

Norwegian Institute of Public Health

View shared research outputs
Top Co-Authors

Avatar

Anders Prestmo

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Ingvild Saltvedt

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Jorunn L. Helbostad

Norwegian University of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Lars Gunnar Johnsen

Norwegian University of Science and Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge